血清降钙素原:纤维板层型肝细胞癌诊断与疾病监测的新型肿瘤标志物
该研究在18例纤维板层型肝细胞癌(FLC)患者中检测血清降钙素原(PCT),并与其他肝病患者及多种肝脏肿瘤样本对比。结果显示FLC患者血清PCT中位数显著升高(55.2 μg/L),83%的FLC病例PCT升高,而HCC和CCA仅3%升高(p<0.0001),提示PCT是FLC敏感且特异的血清标志物。
要点
- FLC患者血清PCT中位数55.2 μg/L,显著高于HCC、CCA和肝硬化患者。
- 83%的FLC病例血清PCT升高,而HCC和CCA病例仅3%升高。
- CALCA在FLC肿瘤中显著过表达,空间转录组定位于肿瘤细胞。
核心结论
- 降钙素原是纤维板层型肝细胞癌敏感且特异的血清标志物,可用于诊断和治疗反应监测。
研究设计与样本
- 研究检测了18例FLC患者的34份血清样本,以及64例HCC、24例CCA和20例肝硬化患者的血清PCT。
- 对27例FLC、331例HCC、39例CCA、71例肝母细胞瘤、34例肝细胞腺瘤和55例非肿瘤肝样本进行RNA测序分析CALCA表达。
- 对3例FLC肿瘤行空间转录组学,对13例FLC和34例其他原发或继发性肝癌行PCT免疫组化。
主要发现
- 欧洲队列8例FLC患者血清PCT中位数为55.2 μg/L,显著高于HCC(0.14 μg/L)、CCA(0.16 μg/L)和肝硬化(0.11 μg/L),p=0.0005。
- 美国队列10例FLC患者验证了上述发现,与HCC和CCA相比p=0.0002。
- 合并队列中,83%的FLC病例血清PCT升高,而HCC和CCA病例仅3%升高,p<0.0001。
- 4例患者血清PCT水平变化与RECIST 1.1影像学缓解相关。
- RNA测序显示CALCA在FLC中较其他原发性肝肿瘤显著过表达(p<0.0001),空间转录组将CALCA表达定位于肿瘤细胞。
关键数值与推荐
- FLC患者血清PCT中位数55.2 μg/L,HCC 0.14 μg/L,CCA 0.16 μg/L,肝硬化0.11 μg/L(p=0.0005)。
- FLC病例血清PCT升高比例83%,HCC和CCA病例3%(p<0.0001)。
- CALCA在FLC中较其他原发性肝肿瘤显著过表达(p<0.0001)。
- 免疫组化显示77%的FLC肿瘤PCT过表达。
临床怎么用
- 血清PCT检测可作为影像学诊断和纵向评估FLC的非侵入性辅助手段。
- PCT可用于FLC治疗反应的监测,其变化与RECIST 1.1影像学缓解相关。
局限性
- 需要更大规模、更多样化队列的前瞻性研究来完善诊断截断值并确认特异性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: Fibrolamellar carcinoma (FLC) is a rare primary liver cancer that predominantly affects young patients with normal known serum tumor biomarkers. An observation of elevated procalcitonin (PCT) in one patient prompted us to investigate PCT as a biomarker in a larger FLC cohort. METHODS: We measured serum PCT levels in 34 samples from 18 patients with FLC and in 64 patients with hepatocellular carcinoma (HCC), 24 with cholangiocarcinoma (CCA), and 20 with cirrhosis. Using RNA sequencing, we analyzed expression of CALCA, which encodes PCT, in 27 FLC tumors, 331 HCC tumors, 39 CCA tumors, 71 hepatoblastomas, 34 hepatocellular adenomas, and 55 non-tumor liver samples. Spatial transcriptomics was performed on three FLC tumors, and PCT immunohistochemistry was performed on 13 FLC tumors and 34 other primary or secondary liver cancers. RESULTS: In eight patients with FLC from the European cohort, median serum PCT was significantly elevated (55.2 μg/L) compared to patients with HCC (0.14 μg/L), CCA (0.16 μg/L), and cirrhosis (0.11 μg/L; p = 0.0005). These findings were validated in a US cohort of 10 patients with FLC compared to HCC and CCA (p = 0.0002). Across these cohorts, elevated serum PCT was observed in 83% of FLC cases vs. 3% of HCC and CCA cases (p <0.0001). In four patients, changes in serum PCT levels correlated with radiologic response according to RECIST 1.1. RNA sequencing demonstrated significant overexpression of CALCA in FLC compared to other primary liver tumors (p <0.0001), and spatial transcriptomics localized CALCA expression specifically to tumor cells. Immunohistochemistry confirmed PCT overexpression in 77% of FLC tumors but not in other liver cancers. CONCLUSION: Procalcitonin is a sensitive and specific serum biomarker for FLC among primary liver cancers, with potential utility for diagnosis and monitoring of treatment response. IMPACT AND IMPLICATIONS: This study is justified by the lack of reliable serum biomarkers for fibrolamellar carcinoma (FLC) and demonstrates that procalcitonin is specifically overexpressed by FLC tumor cells and detectable in the blood of the patients with FLC. These findings are important for clinicians and researchers, as they identify a readily available biomarker that may facilitate diagnosis, improve disease monitoring, and support clinical trial design in a rare cancer that predominantly affects young patients. In clinical practice, serum PCT measurement could be incorporated as a non-invasive adjunct to imaging for the diagnosis and longitudinal assessment of FLC, although prospective studies in larger and more diverse cohorts are needed to refine diagnostic cut-offs and confirm specificity.
引用
- Nault JC, Campani C, Hirsch TZ, et al. Serum procalcitonin: A novel tumor biomarker for diagnosis and disease monitoring in fibrolamellar hepatocellular carcinoma. J Hepatol. 2026. PMID: 41654224. doi:10.1016/j.jhep.2026.01.015
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。